Laddar...

Are We Ready to Use ESR1 Mutations in Clinical Practice?

The recurrent ligand-binding domain ESR1 mutations are an important mechanism of endocrine resistance in estrogen receptor-positive (ER+) metastatic breast cancer. These mutations evolve under the selective pressure of endocrine treatments and are rarely found in treatment-naïve ER+ breast cancers....

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Breast Care (Basel)
Huvudupphovsman: Jeselsohn, Rinath
Materialtyp: Artigo
Språk:Inglês
Publicerad: S. Karger GmbH 2017
Ämnen:
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5704725/
https://ncbi.nlm.nih.gov/pubmed/29234250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000481428
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!